[go: up one dir, main page]

HK1041211A1 - 糖尿病性局部缺血症的基因治療 - Google Patents

糖尿病性局部缺血症的基因治療

Info

Publication number
HK1041211A1
HK1041211A1 HK02102637.3A HK02102637A HK1041211A1 HK 1041211 A1 HK1041211 A1 HK 1041211A1 HK 02102637 A HK02102637 A HK 02102637A HK 1041211 A1 HK1041211 A1 HK 1041211A1
Authority
HK
Hong Kong
Prior art keywords
gene therapy
ischemic disease
diabetic ischemic
diabetic
ischemic
Prior art date
Application number
HK02102637.3A
Other languages
English (en)
Inventor
Morishita Ryuichi
Ogihara Toshio
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Publication of HK1041211A1 publication Critical patent/HK1041211A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
HK02102637.3A 1999-10-29 2002-04-09 糖尿病性局部缺血症的基因治療 HK1041211A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30998499 1999-10-29
PCT/JP2000/007502 WO2001032220A1 (fr) 1999-10-29 2000-10-26 Therapie genique pour traiter les maladies ischemiques diabetiques

Publications (1)

Publication Number Publication Date
HK1041211A1 true HK1041211A1 (zh) 2002-07-05

Family

ID=17999746

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102637.3A HK1041211A1 (zh) 1999-10-29 2002-04-09 糖尿病性局部缺血症的基因治療

Country Status (15)

Country Link
US (3) US20080268030A1 (zh)
EP (1) EP1142590B8 (zh)
JP (1) JP3877148B2 (zh)
KR (1) KR20010108053A (zh)
CN (1) CN1182874C (zh)
AT (1) ATE409494T1 (zh)
AU (1) AU778826B2 (zh)
CA (1) CA2356701C (zh)
CY (1) CY1110445T1 (zh)
DE (1) DE60040383D1 (zh)
DK (1) DK1142590T3 (zh)
ES (1) ES2313907T3 (zh)
HK (1) HK1041211A1 (zh)
PT (1) PT1142590E (zh)
WO (1) WO2001032220A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001026694A1 (fr) 1999-10-08 2001-04-19 Medgene Bioscience, Inc. Therapie genique pour cardiomyopathie
EP1391214A4 (en) 2001-05-09 2006-05-17 Anges Mg Inc GM TRANSFER OF ANGIOGENIC FACTOR IN SKIN DISEASES
AU2002349583B2 (en) * 2001-11-28 2007-11-22 Anges Mg, Inc. Genetic remedies for neurodegenerative diseases
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
US20080213348A1 (en) * 2002-06-06 2008-09-04 Anges Mg, Inc. Agents for gene therapy of cerebrovascular disorders
CA2500278A1 (en) * 2002-10-02 2004-04-15 Anges Mg, Inc. Pharmaceutical preparation for hearing impairment
JP4775940B2 (ja) * 2004-06-29 2011-09-21 アンジェスＭｇ株式会社 アロディニアの治療、改善、予防剤
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
ES2556711T3 (es) * 2008-04-09 2016-01-19 Viromed Co., Ltd. Formulaciones liofilizadas de ADN para el aumento de la expresión del ADN plasmídico
EP2840957B1 (en) * 2012-04-27 2024-01-03 Stryker European Operations Limited Optical coherent imaging medical device and method
MX375916B (es) 2013-10-22 2025-03-07 Helixmith Co Ltd Composicion para prevenir o tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito.
RU2691654C1 (ru) * 2018-06-05 2019-06-17 Юрий Валентинович Червяков Способ лечения хронической ишемии нижних конечностей атеросклеротического генеза при окклюзии бедренной и подколенной артерий
JP7212230B2 (ja) 2018-07-19 2023-01-25 ヘリックスミス カンパニー， リミテッド ネイキッドｄｎａ遺伝子療法のための凍結乾燥した薬剤学的組成物
WO2024186828A1 (en) 2023-03-06 2024-09-12 Wisconsin Alumni Research Foundation Methods of inducing cardiac cell proliferation and inducing heart regeneration

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4576177A (en) * 1983-02-18 1986-03-18 Webster Wilton W Jr Catheter for removing arteriosclerotic plaque
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5631237A (en) * 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5817022A (en) * 1995-03-28 1998-10-06 Sonometrics Corporation System for displaying a 2-D ultrasound image within a 3-D viewing environment
US5756122A (en) * 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
ES2240999T3 (es) * 1995-08-29 2005-10-16 Anges Mg, Inc. Medicamento que contiene un gen del hgf.
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5922685A (en) * 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
US6893664B1 (en) * 1996-06-17 2005-05-17 Powderject Research Limited Particle delivery techniques
EP0922102B1 (en) * 1996-07-03 2010-04-21 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6024703A (en) * 1997-05-07 2000-02-15 Eclipse Surgical Technologies, Inc. Ultrasound device for axial ranging
GB9709453D0 (en) * 1997-05-10 1997-07-02 Imp Cancer Res Tech Polypedtides and their use in therapy
WO1999036103A1 (en) * 1998-01-16 1999-07-22 Mcgill University Prevention and treatment of neuropathy by hepatocyte growth factor
CA2261255A1 (en) * 1998-02-13 1999-08-13 Ethicon, Inc. Assessment of ischemic wound healing therapeutics
US6066123A (en) * 1998-04-09 2000-05-23 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of bioavailability by use of focused energy delivery to a target tissue
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
US7125856B1 (en) * 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
CA2365434A1 (en) * 1999-04-15 2000-10-26 St. Elizabeth's Medical Center Of Boston Angiogenic growth factors for treatment of peripheral neuropathy
US6440945B1 (en) * 1999-05-27 2002-08-27 Instituto Dermopatico Dell'immacolata Method of inducing angiogenesis in nonis chemic skeletal muscle
WO2001026694A1 (fr) * 1999-10-08 2001-04-19 Medgene Bioscience, Inc. Therapie genique pour cardiomyopathie
EP1300158B9 (en) * 2000-06-27 2008-11-19 AnGes MG, Inc. Pharmaceutical compositions for angiogenic therapy
EP1391214A4 (en) * 2001-05-09 2006-05-17 Anges Mg Inc GM TRANSFER OF ANGIOGENIC FACTOR IN SKIN DISEASES
US20060074036A1 (en) * 2002-06-06 2006-04-06 Ryuichi Morishita Agents for gene therapy of cerebrovascular disorders
US20080213348A1 (en) * 2002-06-06 2008-09-04 Anges Mg, Inc. Agents for gene therapy of cerebrovascular disorders
DE60333476D1 (de) * 2002-12-02 2010-09-02 Anges Mg Inc Zusammensetzungen zur behandlung oder prävention von angiogenese-abhängigen symptomen

Also Published As

Publication number Publication date
KR20010108053A (ko) 2001-12-07
EP1142590B1 (en) 2008-10-01
EP1142590A1 (en) 2001-10-10
CA2356701C (en) 2011-02-15
PT1142590E (pt) 2008-10-27
JP3877148B2 (ja) 2007-02-07
CN1339973A (zh) 2002-03-13
EP1142590B8 (en) 2008-11-26
AU1052301A (en) 2001-05-14
DE60040383D1 (de) 2008-11-13
CN1182874C (zh) 2005-01-05
US20110045061A1 (en) 2011-02-24
CY1110445T1 (el) 2015-04-29
WO2001032220A1 (fr) 2001-05-10
DK1142590T3 (da) 2009-01-26
CA2356701A1 (en) 2001-05-10
EP1142590A4 (en) 2005-01-26
US20080268030A1 (en) 2008-10-30
ES2313907T3 (es) 2009-03-16
US20160250290A1 (en) 2016-09-01
AU778826B2 (en) 2004-12-23
ATE409494T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
CY1110445T1 (el) Γονιδιακη θεραπεια για διαβητικη ισχαιμικη ασθενεια
CY1118651T1 (el) Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη
ATE482227T1 (de) Modulatoren pharmakologischer mittel
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
DE60138709D1 (de) Analoge der barbitursäure als therapeutische wirkstoffe
DK1162982T3 (da) Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
DK1137762T3 (da) Behandling af Pompes sygdom
ATE433959T1 (de) Analoge von kokain
DK0988059T3 (da) Humane quinonreduktase-2-konjugater til ADEPT og GDEPT
AU8502198A (en) Method for treating vascular proliferative diseases with p27 and fusions thereof
ATE480256T1 (de) Plazentäre alkalische phosphatase zur diabeteskontrolle
EP0315591A3 (en) Physiologically active substances, a process for the preparation thereof and pharmaceutical compositions containing them
WO2003063791A3 (en) Non-steroidal analogs of 2-methoxyestradiol
ATE444073T1 (de) Oxalate-abbauende mikroorganismen oder oxalate- abbauende enzyme zur verhütung der oxalate- verwandten krankheiten
DE69125855D1 (de) Therapeutisch wirksame, örtliche anwendung von st1435
WO2006074182A3 (en) Growth factor therapy mobilization of stem cells into the peripheral blood
DK2359853T3 (da) Farmaceutiske sammensætninger og fremgangsmåder, der er anvendelige til at modulere antiogenese
NO20014480D0 (no) Fremgangsmåte for å kontrollere vektökning forbundet med terapautiske droger
WO2001005437A3 (en) Methods for treatment of hyperproliferative diseases using human mda-7
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
HUP9800247A2 (hu) Humán endoglin gén promóter és annak alkalmazása
Manning The 2000 Bower Award for Business Leadership presented to William J. Rutter
DK282786A (da) Ergolinderivater, fremgangsmaade til fremstilling deraf og forbindelser til anvendelse som mellemprodukter ved fremgangsmaaden samtfarmaceutiske praeparater
ITRM910756A0 (it) Miscela di biofarmaci somministrabile per fleboterapia nel trattamentodelle patologie neuro-psico-somatiche e organico-vascolari, in particolare arteriopatie diabetiche e nicotiniche, cardiopatie ischemiche, tossicodipendenze, psoriasi